Inflexion Private Equity has held a double fund close for Inflexion Enterprise Fund V and Inflexion Supplemental Fund V on their respective hard-caps of £400m and £600m within 10 weeks of launching.
Backers close a $18.6m round started in 2015 with an initial $10.6m capital injection
GP invests via its Nordic Capital Fund IX, which held a final close on €4.3bn in May 2018
Abalos Therapeutics is a biotechnology company focused on developing immuno-oncology therapeutics
Existing management team will lead the company's future growth and development